(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 6.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.
Bio Techne's revenue in 2024 is $1,154,281,000.On average, 4 Wall Street analysts forecast TECH's revenue for 2024 to be $182,962,224,527, with the lowest TECH revenue forecast at $182,735,145,065, and the highest TECH revenue forecast at $183,444,275,932. On average, 4 Wall Street analysts forecast TECH's revenue for 2025 to be $197,702,061,134, with the lowest TECH revenue forecast at $195,940,737,646, and the highest TECH revenue forecast at $198,856,053,430.
In 2026, TECH is forecast to generate $219,839,393,355 in revenue, with the lowest revenue forecast at $216,239,687,492 and the highest revenue forecast at $223,439,256,802.